Immunotherapy for endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy treatment for advanced or recurrent endometrial cancer. It uses your tumor's genetic features to see if the treatment might work better for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have a type of endometrial cancer (like endometrioid, serous, clear cell, mixed, or carcinosarcoma).
- Your cancer is advanced (stage III or IV) or has come back after treatment, and you need surgery or a biopsy as part of your care.
- You have a tumor sample (fresh or frozen) from surgery or biopsy that has been stored in a biobank.
- Your tumor's mismatch repair status (dMMR or pMMR) has been tested or can be tested.
- You have not had prior treatment with immune checkpoint inhibitors for another cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with endometrial cancer respond well to immunotherapy. It uses samples of your tumor to help doctors better understand how to choose the right treatment for each person.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) for patients with a specific type of endometrial cancer that has a high number of gene mutations (called dMMR or MSI-H). The goal is to shrink or eliminate the tumor so surgery may not be needed.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
Hear when a new pMMR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.